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ABSTRACT: Over the past decade, two independent technologies have
emerged and been widely adopted by the neuroscience community for remotely
controlling neuronal activity: optogenetics which utilize engineered channelrho-
dopsin and other opsins, and chemogenetics which utilize engineered G protein-
coupled receptors (Designer Receptors Exclusively Activated by Designer Drugs
(DREADDs)) and other orthologous ligand−receptor pairs. Using directed
molecular evolution, two types of DREADDs derived from human muscarinic
acetylcholine receptors have been developed: hM3Dq which activates neuronal
firing, and hM4Di which inhibits neuronal firing. Importantly, these DREADDs
were not activated by the native ligand acetylcholine (ACh), but selectively
activated by clozapine N-oxide (CNO), a pharmacologically inert ligand. CNO
has been used extensively in rodent models to activate DREADDs, and although CNO is not subject to significant metabolic
transformation in mice, a small fraction of CNO is apparently metabolized to clozapine in humans and guinea pigs, lessening the
translational potential of DREADDs. To effectively translate the DREADD technology, the next generation of DREADD agonists
are needed and a thorough understanding of structure−activity relationships (SARs) of DREADDs is required for developing
such ligands. We therefore conducted the first SAR studies of hM3Dq. We explored multiple regions of the scaffold represented
by CNO, identified interesting SAR trends, and discovered several compounds that are very potent hM3Dq agonists but do not
activate the native human M3 receptor (hM3). We also discovered that the approved drug perlapine is a novel hM3Dq agonist
with >10 000-fold selectivity for hM3Dq over hM3.
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To elucidate how neuronal ensembles interactively encodehigher brain processes, new and improved methods for
both recording and manipulating neuronal activity will be
required.1,2 The ability to selectively modulate the activity of
defined neuronal populations and to elucidate the behavioral
consequences of this selective neuronal modulation affords
powerful approaches for studying mammalian brain function in
health and disease. Historically, important methods include
Wilder Penfield’s pioneering studies of focal electrical
stimulation of the human cortex.3 The development of the
optogenetics technology pioneered by Diesseroth and
colleagues to visualize and activate neuronal activity with
exquisite temporal resolution using engineered channelrhodop-
sin4,5 and other opsins6 has provided an expanding toolbox for
decoding the neuronal correlates of brain function.4,6−10 More
recently, Designer Receptors Exclusively Activated by Designer
Drugs (DREADDs) have been developed as a powerful
chemogenetics technology for remotely controlling neuronal
activity11,12 and have been widely adopted by the neuroscience
and greater biological communities.13−17
DREADDs, first revealed in 2005,5 were developed using
directed molecular evolution of human muscarinic acetylcho-
line receptors.11,12 After multiple rounds of random muta-
genesis, DREADDs derived from the human muscarinic
acetylcholine M3 receptors (hM3Dq) to be insensitive to the
endogenous ligand acetylcholine (ACh) but potently and
selectively activated by the pharmacologically inert clozapine N-
oxide (CNO) were discovered. Importantly, CNO lacks
appreciable affinity (Ki > 1 μM) for all relevant native CNS
(central nervous system) targets.11,18 The DREADDs have no
detectable constitutive activity in vitro11 and, thus, provide an
attractive orthologous receptor-effector chemogenetic platform
for modifying neuronal activity remotely with minimal
invasiveness. In addition to hM3Dq, which activates neuronal
firing upon the CNO stimulation in part by depolarization and
elevation of intracellular calcium levels,12 hM4Di was
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developed from human muscarinic acetylcholine M4 receptors
for inhibiting neuronal firing via activation of G-protein
inwardly rectifying potassium (GIRK) channels.11 Since the
introduction of the DREADD technology, a large number of
papers have independently validated the utility of excitatory and
inhibitory DREADDs.12,19−32 In addition, no effect related to
the ectopic expression of hM3Dq or hM4Di has been observed.
In addition to being pharmacologically inert, CNO, the
“chemical switch” of this chemogenetic approach, is orally
bioavailability and CNS penetrant19,33−35 and is not subject to
significant metabolic transformation in mice and rats. However,
a small fraction of CNO is apparently metabolized to clozapine
in humans, nonhuman primates and guinea pigs.34,36,37 Because
clozapine modulates the activity of many native CNS
receptors,38 thus interfering with the selective activation of
the DREADDs in defined neuronal populations, the “back-
metabolism” issue presents a hurdle for translating the
DREADD technology forward. To ultimately develop the
next generation of DREADD ligands that can selectively
activate defined neuronal populations in primates including
human, a thorough understanding of structure−activity
relationships (SARs) of DREADDs is needed. To date, no
SAR studies have been reported for any DREADDs including
hM3Dq and hM4Di.
Here, we report the first SAR studies of hM3Dq. We
extensively explored multiple regions of the scaffold repre-
sented by CNO, which resulted in the discovery of compounds
13 and 21 that are very potent hM3Dq agonists but do not
activate the native human M3 receptor (hM3). We describe the
design, synthesis, and pharmacological evaluation of new CNO
analogues and discuss the interesting SAR trends revealed from
the studies. We also report the discovery that perlapine, a
hypnotic agent first reported in 1966,39−41 is a novel, potent,
and selective agonist of hM3Dq (>10 000-fold selective for
hM3Dq over hM3).
■ RESULTS AND DISCUSSION
Design and Synthesis. To understand the SAR of CNO
analogues as hM3Dq agonists, we explored several regions of
the CNO scaffold. In particular, we focused on investigating the
R1 and R2 substituents as well as modifications to the piperazine
ring (highlighted in red in Figure 1). We also studied whether
the chloro group (R3, highlighted in blue in Figure 1) on the
tricyclic core is required and whether a different tricyclic core
(e.g., the core of the perlapine scaffold, see below) can be
tolerated.
We first explored the size of the alkyl group (R1) on the N4′
position of the CNO scaffold and synthesized a set of close
analogues as outlined in Scheme 1. The commercially available
2-((2-amino-4-chlorophenyl)amino)benzoic acid (1) was re-
fluxed in xylene for 48 h to give the cyclized compound 2,
which was then treated with POCl3 and N,N-dimethylaniline in
toluene at 95 °C for 2 h to afford the chloride 3. Compound 3
was reacted with various N-alkylpiperazines in toluene at 120
°C for 2 h to yield compounds 4a−4d, which were then
converted to their corresponding N-oxides 5a−5d by treating
with meta-chloroperoxybenzoic acid (mCPBA) at room
temperature in CH2Cl2 for 10 min. The synthetic route to
compounds 4a − 4d was described previously.42,43
We next synthesized the analogues outlined in Scheme 2 to
determine whether the positive charge of CNO is required for
activating hM3Dq. For example, compound 6, which contains a
quaternary ammonium moiety, has a permanent positive
charge, while compounds 7, 9, 12, and 14 do not possess a
basic amino group and therefore do not contain a positive
charged group. As illustrated in Scheme 2, compound 4a
(clozapine) was converted to the quaternary ammonium iodide
6 by stirring overnight with CH3I in acetone at room
temperature. Compound 3 was treated with piperazin-2-one
at 99 °C overnight in the 1:1 mixture of 1,4-dioxane and
ethanol to give compound 7. Similarly, compound 9 was
produced by treating compound 3 with commercially available
1,3,8-triazaspiro[4.5]decane-2,4-dione (8) in the 2:1 mixture of
1,4-dioxane and N,N-dimethylformamide (DMF) at 130 °C for
24 h. Hydrolysis of compound 9 using 0.5 N aqueous NaOH
solution in 1,2-dimethoxyethane under microwave irradiation
afforded compound 10. Likewise, compound 11 was prepared
from compound 3 and piperazine in toluene at 120 °C for 2 h.
Acetylation of compound 11 by AcCl in CH2Cl2 at 0 °C in the
presence of triethylamine (TEA) yielded compound 12, which
was subsequently reduced to the deuterated compound 13
using LiAlD4 under reflux conditions, followed by quenching
with CD3OD at 0 °C. In addition, compound 11 was reacted
with MsCl in CH2Cl2 at 0 °C in the presence of
diisopropylethylamine (DIPEA) to give the methylsulfonamide
14.
To determine whether the 8-Cl group on the tricyclic core is
required to activate hM3Dq, we prepared compounds 21−23
according to the synthetic route outlined in Scheme 3.44 The
commercially available 2-aminobenzoic acid (15) and 2-
nitrophenyl iodide (16) were subjected to Ullmann coupling
conditions45 to afford the aniline 17. Reduction of the nitro
moiety of compound 17 yielded compound 18, which was
refluxed in xylene to generate the benzodiazepine 19.
Treatment of compound 19 with POCl3 provided the chloride
20, which was then displaced with piperazine to afford
compound 21. Similarly, compound 22 was prepared by the
displacement reaction of the chloride 20 with 1-ethylpiperazine
in toluene under reflux conditions. In addition, the oxidation of
compound 22 by mCPBA in CH2Cl2 afforded the N-oxide 23.
Biological Evaluation. The newly synthesized compounds
were evaluated in the hM3Dq and hM3 Ca2+ mobilization
fluorometric imaging plate reader (FLIPRTETRA) assays
according to the protocols reported previously.11,46,47 Agonist
activities of these compounds in the hM3Dq and hM3
functional assays are summarized in Table 1.
For the size of the N-alkyl group in compounds 4a−4d and
5a−5d, we observed a clear trend showing that the longer and/
or bulkier the N-alkyl group, the weaker the compounds’
potency for hM3Dq. The replacement of the methyl group in
compounds 4a and 5a with the n-propyl group in compounds
4d and 5d resulted in a potency decrease of approximately 70-
and 100-fold, respectively. In addition to the loss in potency,
the compounds with a longer or bulkier N-alkyl group (e.g.,
compounds 4b−4d and 5b−5d) in general displayed lower
Figure 1. SAR studies of the CNO scaffold.
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agonist efficacy for hM3Dq and became partial agonists of
hM3Dq rather than full agonists as seen for compounds 4a and
5a. Interestingly, compounds 4c and 5c, which contain an i-
propyl group, were more potent than compounds 4d and 5d,
Scheme 1. Synthesis of N4′-alkyl Substituted CNO Analoguesa
aReagents and conditions: (a) xylene, reflux, 48 h, 95% yield; (b) POCl3, N,N-dimethylaniline, toluene, 95 °C, 2 h, 67% yield; (c) N-alkylpiperazines,
toluene, 120 °C, 2 h, 69−80% yield; and (d) mCPBA, CH2Cl2, rt, 10 min, 65−75% yield.
Scheme 2. Synthesis of Compounds 6, 7, and 9−14a
aReagents and conditions: (a) CH3I, acetone, rt, overnight, 55% yield; (b) 2-oxypiperazine, 1,4-dioxane/ethanol 1:1, 99 °C, overnight, 65% yield; (c)
1,3,8-triazaspiro[4.5]decane-2,4-dione (8), 1,4-dioxane/DMF (2:1), 130 °C, 24 h, 66% yield; (d) 1,2-dimethoxyethane, 0.5 N NaOH, microwave,
150 °C, 10 min, 16% yield; (e) piperazine, toluene, 120 °C, 2 h, 69% yield; (f) AcCl, TEA, CH2Cl2, 0 °C, 1 h, 86% yield; (g) (1) LiAlD4, THF, N2,
reflux, 2h, (2) CD3OD, 0 °C, (3) NH4OH, 0 °C, 84% yield; (h) MsCl, DIPEA, CH2Cl2, 0 °C, 1 h, 93% yield.
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which contain a n-propyl group, suggesting that the length of
the N-alkyl group plays a more significant role than the
bulkiness of the N-alkyl group in reducing agonist potency. We
were also pleased to find that compounds 4b−4d and 5b−5d
did not display any agonist activity (EC50 > 30 000 nM) for the
native human M3 receptor (hM3), in contrast to compound 4a
(clozapine), which was a hM3 agonist with sub-μM potency. In
addition, compounds 4a−4d were in general more potent than
their corresponding N-oxides 5a−5d at activating hM3Dq,
suggesting that the negative charge on the N-oxides is not only
not required for activating hM3Dq, but also reduces agonist
potency.
The quaternary ammonium salt 6 was an extremely potent
full agonist of hM3Dq with an EC50 value of 69 pM and about
15-fold more potent than compound 4a (clozapine). However,
compound 6 was also a potent full agonist of hM3 (EC50 = 9.5
nM, Emax = 92) even though it achieves >100-fold higher
potency for hM3Dq over hM3. On the other hand, compounds
7, 12, and 14, which do not contain a basic amino group or a
group with permanent positive charge, did not display any
agonist activity for hM3Dq. As expected, these compounds did
not activate hM3 either. Taken together, these results suggest
that either a basic amino group as in compounds 4a and 4b or a
group with permanent positive charge as in compounds 5a and
6 is required to retain hM3Dq agonist activity. In addition,
compound 9 that contains a hydantoin moiety and compound
10 that contains an amino acid moiety in this region did not
activate hM3Dq and hM3. On the other hand, compound 11,
which is the des-methyl clozapine, showed similar potency and
efficacy for hM3Dq and hM3 as clozapine, suggesting that the
N-methyl group is not required for activating hM3Dq.
Interestingly, compound 13, which is a deuterated analogue
of compound 4b, exhibited similar potency and efficacy (EC50
= 9.6 nM, Emax = 86%) for hM3Dq as compounds 4b and 5a
(CNO) (Figure 2). Importantly, compound 13 did not display
any agonist activity for hM3. Because compound 13 contains an
α,α-dideutero ethyl group, it is likely that the N-dealkylation,
the major metabolic pathway that converts clozapine to des-
methyl clozapine,34,36 will be significantly reduced on the basis
of the well-documented primary kinetic isotope effect48 in
similar systems.49,50
We were also pleased to find that the 8-chloro group was not
required to maintain high agonist potency and efficacy for
hM3Dq. In particular, compound 21 was a potent full agonist
(EC50 = 1.7 nM, Emax = 100%) of hM3Dq (Figure 2). In
contrast to compound 11, a full hM3 agonist with sub-
micromolar potency, compound 21 displayed little agonist
Scheme 3. Synthesis of Compounds 22−24a
aReagents and conditions: (a) K2CO3, Cu, 3-methylbutan-1-ol, reflux, 4 h; (b) NaS2O4, NH4OH/H2O 3:2, 80 °C, 30 min, 75% yield in two steps;
(c) xylene, reflux, Dean−Stark conditions, 48 h, 96% yield; (d) POCl3, N,N-dimethylaniline, toluene, reflux, 3 h, 52% yield; (e) piperazine, toluene,
reflux, overnight, 63% yield; (f) 1-ethylpiperazine, toluene, reflux, 2 h, 72% yield; and (g) mCPBA, CH2Cl2, rt, 10 min, 78% yield.
Table 1. Agonist Activities of New Compounds in hM3Dq




to CNO) EC50 (nM)
Emax (relative to
acetylcholine)
4a 1.1 95 360 88
4b 7.0 91 >30 000 NA
4c 13 45 >30 000 NA
4d 71 50 >30 000 NA
5a 6.0 100 >30 000 NA
5b 19 50 >30 000 NA
5c 190 45 >30 000 NA
5d 740 79 >30 000 NA
6 0.069 100 9.5 92
7 >30 000 NA >30 000 NA
9 >30 000 NA >30 000 NA
10 >30 000 NA >30 000 NA
11 2.1 95 490 86
12 >30 000 NA >30 000 NA
13 9.6 86 >30 000 NA
14 >30 000 NA >30 000 NA
21 1.7 100 NA ∼20
22 1.3 81 >30 000 NA
23 220 59 >30 000 NA
aEC50 values are the average of at least two duplicate experiments with
standard deviation (SD) values that are 3-fold less than the average.
NA: not applicable.
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activity for hM3 (Emax = ∼20%). In addition, compound 22 was
found to be a potent hM3Dq agonist (EC50 = 1.3 nM, Emax =
81%), which was more potent than the corresponding chloro
analogue, compound 4b (EC50 = 7.0 nM, Emax = 91%). On the
other hand, the N-oxide 23 (EC50 = 220 nM, Emax = 59%) was
about 10-fold less potent for hM3Dq than compound 5b, the
corresponding chloro analog (EC50 = 19 nM, Emax = 50%).
Similar to compound 21, both compounds 22 and 23 did not
exhibit any agonist activity for hM3.
We next selected a subset of the above hM3Dq agonists that
are inactive against hM3 and assessed their binding affinities to
other aminergic GPCRs. Because compound 4a (clozapine)
showed high binding affinities to 5HT2A and 5HT2C serotonin,
α1A adrenergic, and H1 histamine receptors with Ki values of
5.4, 9.4, 1.6, and 1.1 nM, respectively (Table 2), we tested
compounds 4b, 4c, 5b, 5c, 13, and 21 in 5HT2A, 5HT2C, α1A,
and H1 radioligand binding assays. The assay results are
summarized in Table 2.
Compounds 4b and 4c had reduced binding affinities to
5HT2A, 5HT2C, and α1A (Ki = 16−46 nM) compared with
compound 4a (clozapine), but retained high binding affinities
to H1 (Ki < 5.0 nM). On the other hand, the N-oxide 5b
displayed weak binding affinities for 5HT2A, 5HT2C, and α1A (Ki
> 1000 nM) and was about 8-fold selective for hM3Dq over H1,
while the N-oxide 5c displayed poor binding affinities to
5HT2A, 5HT2C, and H1 (Ki > 5000 nM) but was only about 2-
fold selective for hM3Dq over α1A. Interestingly, compound 13,
a deuterated analogue of compound 4b, exhibited reduced
binding affinities to all four receptors compared with
compound 4b. Compound 13 was selective for hM3Dq over
5HT2A (7-fold), 5HT2C (29-fold), and α1A (7-fold), but was not
selective over H1. We were pleased to find that compound 21
displayed much improved selectivity compared with compound
4a (clozapine). In addition to being inactive at hM3, compound
21, a potent full agonist of hM3Dq (EC50 = 1.7 nM), was 40-
fold selective over 5HT2A, 100-fold selective over 5HT2C, and
165-fold selective over α1A. Although it was only 3.5-fold
selective for hM3Dq over H1, the overall selectivity profile of
compound 21 is significantly better than compound 4a
(clozapine).
Lastly, to identify an alternative compound that might
activate hM3Dq, we conducted a screen of the commercially
available Library Of Pharmaceutically Active Compounds
(LOPAC; N = 1280 compounds) and Prestwick Chemical
Library (N = 1280 compounds) using the hM3Dq FLIPR assay.
From this screen, we discovered perlapine as a novel, potent
agonist of hM3Dq (Figure 3). Importantly, perlapine was
>10 000-fold selective for hM3Dq over hM3. Interestingly,
perlapine contains a different tricyclic core in comparison with
CNO. The high hM3Dq potency of perlapine suggests that the
benzodiazepine tricyclic core of the CNO (compound 5a)
scaffold is not required for maintaining high hM3Dq agonist
activity.
■ CONCLUSION
In summary, we conducted the first SAR studies for hM3Dq, a
chemogenetic platform for activating neuronal firing, by the
design, synthesis, and pharmacological evaluation of new CNO
analogues. We explored multiple regions of the CNO scaffold
and observed the following interesting SAR trends: (1) a longer
or bulkier N-alkyl group as in compounds 4c, 4d, 5c, and 5d
reduces both potency and efficacy for hM3Dq; (2) a basic
amino group as in compounds 4a and 4b or a permanent
positive charge group as in compounds 5a and 6 is required to
retain hM3Dq agonist activity; (3) the negative change on the
N-oxides such as 5a−5d reduces hM3Dq agonist potency; (4)
the 8-chloro group is not required to maintain high agonist
potency and efficacy for hM3Dq; and (5) modifications to the
benzodiazepine tricyclic core of CNO is tolerated. From these
SAR studies, we discovered several compounds such as 13 and
21, which are very potent full agonists of hM3Dq but do not
activate the native human M3 receptor (hM3). In addition, the
selectivity of compound 21 against a number of aminergic
GPCRs is significantly improved compared with clozapine.
Figure 2. Compounds 13 and 21 are potent hM3Dq agonists and do not activate hM3 being similar to compound 5a (CNO). The endogenous
ligand acetylcholine (ACh), on the other hand, is a potent hM3 agonist and does not activate hM3Dq.
Table 2. Binding Affinities of Selected hM3Dq Agonists to
Other GPCRsa
Ki (nM)
compd 5HT2A 5HT2C α1A H1
4a 5.4 9.4 1.6 1.1
4b 29 24 46 1.9
4c 16 17 37 4.6
5b 1900 5100 >10 000 160
5c 5200 6700 320 6200
13 71 280 67 5.0
21 66 170 280 6.0
aKi values are the average of at least 2 duplicate experiments with
standard deviation (SD) values that are 3-fold less than the average.
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Furthermore, we discovered perlapine as a novel, potent
hM3Dq agonist, which is >10 000-fold selective for hM3Dq
over hM3. These SAR studies lay the foundation for developing
the next generation of DREADD ligands that can selectively
activate defined neuronal populations in primates.
■ METHODS
Chemistry. General Methods. HPLC spectra of all compounds
were acquired from an Agilent 6110 Series system with UV detector
set to at 220 nm. Samples were injected (5 μL) onto an Agilent Eclipse
Plus 4.6 × 50 mm, 1.8 μM, C18 column at room temperature. A linear
gradient from 10% to 100% B (MeOH + 0.1% acetic acid) in 5.0 min
was followed by pumping 100% B for another 2 min with A being H2O
+ 0.1% acetic acid. The flow rate was 1.0 mL/min. Mass spectra (MS)
data were acquired in positive ion mode using an Agilent 6110 single
quadrupole mass spectrometer with an electrospray ionization (ESI)
source. HRMS analysis was conducted on an Agilent Technologies
G1969A high-resolution API-TOF mass spectrometer attached to an
Agilent Technologies 1200 HPLC system. Samples were ionized by
electrospray ionization (ESI) in positive mode. Nuclear magnetic
resonance (NMR) spectra were recorded on a Varian Mercury
spectrometer with 400 MHz for proton (1H NMR) and 100 MHz for
carbon (13C NMR); chemical shifts are reported in ppm (δ).
Preparative HPLC was performed on Agilent Prep 1200 series with
UV detector set to at 220 nm. Samples were injected onto a
Phenomenex Luna 75 × 30 mm, 5 μM, C18 column at room
temperature. The flow rate was 30 mL/min. Different linear gradient
for different compounds were used with A being H2O + 0.5% TFA and
B being MeOH.
Compounds 2,42,43 3,42,43 4a,42,43 4b,42 and 5a33,51 were prepared
according to the procedures described previously.
8-Chloro-11-(4-isopropylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]-
diazepine (4c). A solution of 8,11-dichloro-5H-dibenzo[b,e][1,4]-
diazepine (3, 0.397 g, 1.44 mmol) and 1-isopropylpiperazine (1 g,
7.799 mmol) in 1,4-dioxane (20 mL) was stirred overnight at 120 °C.
After cooling down, the reaction mixture was concentrated and the
residue was dissolved with 50 mL of EtOAc. The resulting solution
was washed with 30 mL of aqueous NaHCO3. The organic layer was
dried over Na2SO4, and the filtrate was concentrated and the residue
was purified by flash column chromatography with 5−10% MeOH in
CH2Cl2 to give the desired product 4c (0.410 g) in 80% yield:
1H
NMR (400 MHz, CDCl3) δ 7.38−7.16 (m, 2H), 7.04 (d, J = 1.5 Hz,
1H), 6.99 (t, J = 7.5 Hz, 1H), 6.88−6.72 (m, 2H), 6.58 (d, J = 8.3 Hz,
1H), 4.86 (s, 1H), 3.46 (br, s, 4H), 2.70 (quin, J = 6.5 Hz, 1H), 2.58
(br s, 4H), 1.06 (d, J = 6.5 Hz, 6H). 13C NMR (101 MHz,, CDCl3) δ
162.84, 152.90, 142.13, 140.59, 132.00, 130.55, 129.24, 126.94, 123.69,
123.18, 123.13, 120.25, 120.15, 54.80 (2C), 48.95 (2C), 47.77, 18.80
(2C). HPLC purity 100%, RT 4.099 min. MS (ESI) 355.2 [M + H]+.
HRMS (ESI) calcd for C20H24ClN4
+ [M + H]+: 355.1689. Found:
355.1693.
8-Chloro-11-(4-propylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]-
diazepine (4d). Compound 4d (0.380 g, 70% yield) was prepared via
the same procedure as preparing compound 4c from 8,11-dichloro-
5H-dibenzo[b,e][1,4]diazepine (3, 0.400 g, 1.52 mmol), 1-propylpi-
perazine HCl salt (0.500 g, 3.04 mmol), and DIPEA (2 mL, 11.48
mmol) in 1,4-dioxane (20 mL). 1H NMR (400 MHz, CDCl3) δ 7.31−
7.19 (m, 2H), 7.04 (d, J = 2.3 Hz, 1H), 6.99 (t, J = 7.5 Hz, 1H), 6.79
(dd, J = 8.2, 2.0 Hz, 2H), 6.58 (d, J = 8.3 Hz, 1H), 4.86 (s, 1H), 3.45
(br s, 4H), 2.50 (br s, 4H), 2.33 (t, J = 7.6 Hz, 2H), 1.52 (sixtet, J = 7.6
Hz, 2H), 0.90 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ
162.93, 152.90, 142.08, 140.59, 132.03, 130.52, 129.25, 126.96, 123.69,
123.21, 123.20, 120.26, 120.16, 60.93 (2C), 53.40 (2C), 47.47, 20.21,
12.18. HPLC purity 100%, RT 4.113 min. MS (ESI) 355.2 [M + H]+.
HRMS (ESI) calcd for C20H24ClN4
+ [M + H]+: 355.1689. Found:
355.1687.
4-(8-Chloro-5H-dibenzo[b,e][1,4]diazepin-11-yl)-1-ethylpipera-
zine N-oxide (5b). A solution of compound 4b (0.100 g, 0.293 mmol)
in CH2Cl2 (5 mL) was treated with mCPBA (0.064 g, 0.371 mmol) at
room temperature. After 10 min, the reaction was completed. The
resulting mixture was concentrated and purified by flash column
chromatography with 5−15% C (2% NH4OH in MeOH) in CH2Cl2
to give the desired N-oxide compound 5b (0.073 g,) in 70% yield: 1H
NMR (400 MHz, MeOH-d4) δ 7.39−7.34 (m, 1H), 7.32 (dd, J = 7.8,
1.2 Hz, 1H), 7.05 (t, J = 7.5 Hz, 1H), 7.01 (d, J = 8.0 Hz, 1H), 6.97 (d,
J = 2.3 Hz, 1H), 6.87 (dd, J = 8.4, 2.4 Hz, 1H), 6.81 (d, J = 8.4 Hz,
1H), 3.88 (br s, 2H), 3.74 (t, J = 12.1 Hz, 2H), 3.55−3.43 (m, 2H),
3.367 (q, J = 7.2 Hz, 2H), 3.19−3.09 (m, 2H), 1.38 (t, J = 7.2 Hz, 3H).
13C NMR (101 MHz, CDCl3) δ 162.06, 153.18, 141.54, 140.62,
132.57, 130.29, 129.35, 126.98, 123.90, 123.56, 122.96, 120.45, 120.43,
66.73 (2C), 63.23 (2C), 42.23, 7.69. HPLC purity 100%, RT 4.394
min. MS (ESI) 357.2 [M + H]+. HRMS (ESI) calcd for
C19H22ClN4O
+ [M + H]+: 357.1482. Found: 357.1481.
4-(8-Chloro-5H-dibenzo[b,e][1,4]diazepin-11-yl)-1-isopropylpi-
perazine N-oxide (5c). Compound 5c (0.068 g, 65% yield) was
prepared similarly as 5b from compound 4c (0.100 g, 0.282 mmol)
and mCPBA (0.063 g, 0.365 mmol) in CH2Cl2 (5 mL).
1H NMR (400
MHz, MeOH-d4) δ 7.39−7.30 (m, 2H), 7.05 (t, J = 7.5 Hz, 1H), 7.01
(d, J = 7.9 Hz, 1H), 6.97 (d, J = 2.3 Hz, 1H), 6.87 (dd, J = 8.4, 2.4 Hz,
1H), 6.81 (d, J = 8.4 Hz, 1H), 3.90 (br s, 2H), 3.73 (t, J = 11.9 Hz,
1H), 3.57−3.40 (m, 3H), 3.19−3.12 (m, 2H), 1.38 (d, J = 6.5 Hz,
3H). 13C NMR (101 MHz, CDCl3) δ 162.02, 153.15, 141.64, 140.61,
132.51, 130.31, 129.38, 126.97, 123.81, 123.55, 123.01, 120.43, 120.39,
70.99 (2C), 60.41 (2C), 42.27, 16.54 (2C). HPLC purity 100%, RT
4.305 min. MS (ESI) 371.2 [M + H]+. HRMS (ESI) calcd for
C20H24ClN4O
+ [M + H]+: 371.1639. Found: 371.1642.
Figure 3. Perlapine is a potent full agonist of hM3Dq and does not activate hM3. CNO (compound 5a) was used as a positive control in the hM3Dq
FLIPR assay, and acetylcholine (ACh) was used as a positive control in the hM3 FLIPR assay.
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4-(8-Chloro-5H-dibenzo[b,e][1,4]diazepin-11-yl)-1-propylpipera-
zine N-oxide (5d). Compound 5d (0.075 g, 72% yield) was prepared
using the same procedure as preparing 5b from compound 4d (0.100
g, 0.282 mmol) and mCPBA (0.063 g, 0.365 mmol) in CH2Cl2 (5
mL). 1H NMR (400 MHz, MeOH-d4) δ 7.39−7.34 (m, 1H), 7.32 (dd,
J = 7.8, 1.2 Hz, 1H), 7.05 (t, J = 7.5 Hz, 1H), 7.00 (d, J = 8.0 Hz, 1H),
6.97 (d, J = 2.3 Hz, 1H), 6.87 (dd, J = 8.4, 2.4 Hz, 1H), 6.81 (d, J = 8.4
Hz, 1H), 3.86 (br s, 2H), 3.74 (t, J = 11.9 Hz, 3H), 3.57−3.44 (m,
2H), 3.29−3.21 (m, 2H), 3.20−3.10 (m, 2H), 2.00−1.84 (m, 2H),
1.00 (t, J = 7.4 Hz, 3H); 13C NMR (101 MHz, MeOH-d4) δ 164.31,
155.62, 143.36, 142.96, 133.85, 131.29, 129.72, 127.45, 124.99, 124.29,
124.04, 121.68, 121.53, 73.69 (2C), 64.26 (2C), 43.23, 16.42, 11.37.
HPLC purity 100%, RT 4.439 min. MS (ESI) 371.2 [M + H]+. HRMS
(ESI) calcd for C20H24ClN4O
+ [M + H]+: 371.1639. Found: 371.1640.
4-(8-Chloro-5H-dibenzo[b,e][1,4]diazepin-11-yl)-1,1-dimethylpi-
perazin-1-ium iodide (6). A solution of 4a (0.100 g, 0.306 mmol) in
acetone (5 mL) was treated with methyl iodide (21 μL, 0.337 mmol)
at room temperature. After overnight, the resulting mixture was
concentrated, dissolved in 1 mL of MeOH, and diluted with 10 mL of
distilled water. The aqueous solution was washed with EtOAc (2 × 10
mL) and concentrated. The residue was purified by preparative HPLC
to give the compound 6 (0.079 g) in 55% yield: 1H NMR (400 MHz,
MeOH-d4) δ 7.57 (t, J = 7.7 Hz, 1H), 7.49 (d, J = 7.9 Hz, 1H), 7.26
(d, J = 2.3 Hz, 1H), 7.27−7.13 (m, 3H), 7.00 (d, J = 8.5 Hz, 1H), 4.03
(br s, 4H), 3.72 (br s, 4H), 3.33 (s, 6H). 13C NMR (101 MHz,
MeOH-d4) δ 166.47, 156.55, 145.82, 136.58, 135.26, 132.80, 130.24,
128.46, 126.86, 125.08, 122.75, 122.70, 119.64, 61.86 (2C), 52.46
(2C), 44.44 (2C). HPLC purity 100%, RT 3.893 min. MS (ESI) 341.2
[M − I]+.
4-(8-Chloro-5H-dibenzo[b,e][1,4]diazepin-11-yl)piperazin-2-one
(7). A solution of compound 3 (0.200 g, 0.760 mmol) and 2-
oxypiperazine (0.152 g, 1.52 mmol) in a 1:1 mixture of 1,4-dioxane
and ethanol (15 mL) was stirred overnight at 99 °C. After
concentration, the residue was diluted with EtOAc (50 mL) and the
solution was washed with 20 mL of aqueous NaHCO3. The organic
layer was dried over Na2SO4 and the filtrate was concentrated. The
residue was purified by flash column chromatography with 30−50%
EtOAc in hexanes to afford the desired product (0.162 g) in 65% yield:
1H NMR (400 MHz, CDCl3) δ 7.30 (t, J = 7.6 Hz, 1H), 7.23 (d, J =
7.8 Hz, 1H), 7.05 (s, 1H), 7.02 (t, J = 7.6 Hz, 1H), 6.84 (d, J = 8.3 Hz,
1H), 6.81 (d, J = 7.9 Hz, 1H), 6.60 (d, J = 8.3 Hz, 1H), 6.03 (s, 1H),
4.90 (s, 1H), 4.10 (s, 2H), 3.67 (br s, 2H), 3.50 (br s, 2H). 13C NMR
(101 MHz, CDCl3) δ 168.89, 161.84, 153.15, 141.39, 140.49, 132.63,
130.04, 129.37, 127.19, 124.02, 123.52, 122.99, 120.48, 120.39, 51.47,
44.12, 41.15; HPLC purity 100%, RT 4.681 min. MS (ESI) 327.1 [M
+ H]+. HRMS (ESI) calcd for C17H16ClN4O
+ [M + H]+: 327.1007.
Found: 327.1006.
8-(8-Chloro-5H-dibenzo[b,e][1,4]diazepin-11-yl)-1,3,8-
triazaspiro[4.5]decane-2,4-dione (9). A mixture of compound 3
(0.250 g, 0.951 mmol) and commercially available compound 8 (0.200
g, 1.18 mmol) in 20 mL of a mixture of 1,4-dioxane and DMF (2:1)
was heated to 130 °C for 24 h. The reaction mixture was cooled down
to room temperature and concentrated. The residue was purified by
flash column chromatography with 0−10% MeOH in CH2Cl2 to give
the desired product 9 (0.250 g) in 66% yield: 1H NMR (400 MHz,
CDCl3) δ 8.62 (s, 1H), 7.37−7.17 (m, 2H), 7.10−7.03 (m, 2H), 7.01
(t, J = 7.5 Hz, 1H), 6.85−6.76 (m, 2H), 6.62 (d, J = 8.3 Hz, 1H), 5.06
(s, 1H), 3.90 (br s, 2H), 3.20 (br s, 2H), 2.18−2.05 (m, 2H), 1.74 (s,
2H). 13C NMR (101 MHz, CDCl3) δ 176.84, 163.26, 156.74, 152.90,
141.62, 140.70, 132.47, 130.29, 129.42, 126.97, 123.82, 123.59, 123.43,
120.48, 62.15 (2C), 43.28, 33.19 (2C). HPLC purity 100%, RT 4.289
min. MS (ESI) 396.1 [M + H]+. HRMS (ESI) calcd for
C20H19ClN5O2
+ [M + H]+: 396.1222. Found: 396.1221.
4-Amino-1-(8-chloro-5H-dibenzo[b,e][1,4]diazepin-11-yl)-
piperidine-4-carboxylic acid (10). A solution of compound 9 (0.100
g, 0.253 mmol) in 1,2-dimethoxyethane (5 mL) was treated with 5 mL
of 0.5 N NaOH at room temperature. The resulting mixture was
heated under microwave for 10 min (max power 100 W, max
temperature 150 °C, max pressure 17.0 bar). After cooling down to
room temperature, the reaction mixture was quenched with 10% citric
acid and filtered. The filtrated was purified with preparative HPLC to
afford the desired product (0.015 g) in 16% yield: 1H NMR (400
MHz, MeOH-d4) δ 7.63 (t, J = 7.7 Hz, 1H), 7.54 (d, J = 8.0 Hz, 1H),
7.34 (d, J = 19.4 Hz, 1H), 7.25 (t, J = 7.9 Hz, 3H), 7.08 (d, J = 8.6 Hz,
1H), 4.36−3.59 (m, 4H), 2.70−2.40 (m, 2H), 2.40−2.01 (m, 2H).
HPLC purity 100%, RT 3.585 min. MS (ESI) 371.2 [M + H]+. HRMS
(ESI) calcd for C19H20ClN4O2
+ [M + H]+: 371.1269. Found:
371.1264.
Compound 11 was prepared according to the previously published
procedures.42
1-(4-(8-Chloro-5H-dibenzo[b,e][1,4]diazepin-11-yl)piperazin-1-
yl)ethanone (12). To the solution of compound 10 (0.400 g, 1.28
mmol) and TEA (0.27 mL, 2.0 mmol) in CH2Cl2 was added AcCl
(0.10 mL, 1.4 mmol) at 0 °C. The resulting mixture was then stirred at
0 °C for 1 h. After removing the solvents, the residue was purified by
flash column chromatography with 0−5% MeOH in CH2Cl2 to give
the desired product 12 (0.390 g, 1.10 mmol) in 86% yield: 1H NMR
(400 MHz, CDCl3) δ 7.30 (td, J = 7.7, 1.5 Hz, 1H), 7.26−7.22 (m,
1H), 7.04 (d, J = 2.4 Hz, 1H), 7.02 (td, J = 7.6, 1.0 Hz, 1H), 6.86−6.77
(m, J = 2.4 Hz, 2H), 6.60 (d, J = 8.3 Hz, 1H), 4.89 (s, 1H), 3.67 (br s,
2H), 3.59−3.46 (m, 4H), 3.34 (br s, 2H), 2.11 (s, J = 11.5 Hz, 3H).
13C NMR (101 MHz, CDCl3) δ 169.41, 162.90, 153.15, 141.57,
140.65, 132.40, 130.20, 129.25, 126.97, 123.75, 123.39, 123.32, 120.42,
120.34, 47.80, 47.26, 46.13, 41.50, 21.62. HPLC purity 100%, RT
4.919 min. MS (ESI) 355.2 [M + H]+. HRMS (ESI) calcd for
C19H20ClN4O
+ [M + H]+: 355.1320. Found: 355.1315.
8-Chloro-11-[4-(1,1-dideutrioethyl)piperazin-1-yl]-5H-dibenzo-
[b,e][1,4]diazepine (13). To the solution of compound 12 (0.100 g,
0.282 mmol) in 15 mL of anhydrous THF was added LiAlD4 (0.024 g,
0.572 mmol) at room temperature under N2 atmosphere. The reaction
mixture was heated under reflux conditions for 2 h. The reaction was
quenched with 0.1 mL of CD3OD at 0 °C. The resulting mixture was
treated with 0.5 mL of NH4OH at 0 °C and filtered through Celite and
the filtrate was concentrated. The residue was purified by flash column
chromatography with 0−10% MeOH in CH2Cl2 to give the desired
product 13 (0.081 g) in 84% yield: 1H NMR (400 MHz, CDCl3) δ
7.33−7.23 (m, 3H), 7.06 (d, J = 2.4 Hz, 1H), 7.01 (td, J = 7.6, 1.0 Hz,
1H), 6.81 (dd, J = 8.3, 2.4 Hz, 2H), 6.60 (d, J = 8.3 Hz, 1H), 4.88 (s,
1H), 3.49 (br, s, 4H), 2.54 (br, s, 4H), 1.10 (s, 3H); 13C NMR (101
MHz, CDCl3) δ 162.90, 152.87, 142.03, 140.59, 132.02, 130.46,
129.17, 126.91, 123.60, 123.17, 120.24, 120.16, 52.87 (2C), 51.78 (q, J
= 20.0 Hz), 47.44, 11.86 (2C). HPLC purity 100%, RT 4.072 min; MS
(ESI) 343.2 [M+1]+. HRMS (ESI) calcd for C19H20D2ClN4
+ [M +
H]+: 343.1653. Found: 343.1653.
8-Chloro-11-(4-(methylsulfonyl)piperazin-1-yl)-5H-dibenzo[b,e]-
[1,4]diazepine (14). To a solution of compound 11 (0.102 g, 0.326
mmol) and DIPEA (87 μL, 0.907 mmol) in 10 mL of CH2Cl2, MsCl
(27.8 μL, 0.359 mmol) was added at 0 °C. After 1 h, the reaction was
completed. The reaction mixture was diluted with 50 mL of CH2Cl2
and washed with 10 mL of aqueous NaHCO3. The organic layer was
dried over Na2SO4, and the filtrate was concentrated and the residue
was purified by flash column chromatography with 50% EtOAc in
hexanes to give the desired product 14 (0.118 g) in 93% yield: 1H
NMR (400 MHz, CDCl3) δ 7.31 (t, J = 7.7 Hz, 1H), 7.22 (d, J = 7.8
Hz, 1H), 7.08−6.96 (m, 2H), 6.87−6.78 (m, 2H), 6.61 (d, J = 8.3 Hz,
1H), 4.90 (s, 1H), 3.57 (br s, 4H), 3.29 (br s, 4H), 2.79 (s, 3H). 13C
NMR (101 MHz, DMSO-d6) δ 162.44, 154.11, 142.23, 141.48, 132.24,
129.80, 126.69, 125.58, 122.88, 122.64, 122.40, 120.69, 120.40, 46.33,
45.14 (2C), 33.85 (2C). HPLC purity 100%, RT 4.752 min. MS (ESI)
391.1 [M + H]+. HRMS (ESI) calcd for C18H20ClN4O2S
+ [M + H]+:
391.0990. Found: 391.0994.
Compounds 17−21 were prepared according to the previously
reported procedures.44
11-(Piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine (21). 1H NMR
(400 MHz, MeOH-d4) δ 7.39−7.24 (m, 1H), 7.06−6.95 (m, 3H),
6.94−6.82 (m, 3H), 3.34 (br s, 1H), 2.96−2.85 (m, 2H). 13C NMR
(101 MHz, MeOH-d4) δ 165.39, 156.04, 145.04, 141.55, 133.31,
131.47, 127.85, 125.34, 124.88, 124.66, 123.78, 121.26, 120.71, 46.47.
HPLC purity 99%, RT 2.772 min. MS (ESI) 279.2 [M+1]+. HRMS
(ESI) calcd for C17H19N4
+ [M + H]+: 279.1604. Found: 279.1610.
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11-(4-Ethylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine (22). A
solution of compound 20 (0.420 g, 1.84 mmol) and 1-ethylpiperazine
(1.5 mL, 11.81 mmol) in toluene (20 mL) was heated under reflux
conditions for 2 h. After cooling down to room temperature and
concentration, the residue was purified by flash column chromatog-
raphy with 0−10% MeOH in CH2Cl2 to give the desired product 22
(0.409 g) in 72% yield: 1H NMR (400 MHz, CDCl3) δ 7.30−7.18 (m,
2H), 7.06 (dd, J = 7.8, 1.5 Hz, 1H), 7.00−6.90 (m, 2H), 6.84 (tt, J =
7.3, 3.7 Hz, 1H), 6.80 (dd, J = 7.4, 1.1 Hz, 1H), 6.67 (dd, J = 7.7, 1.4
Hz, 1H), 4.89 (s, 1H), 3.45 (br s, 4H), 2.53 (br s, 4H), 2.46 (q, J = 7.2
Hz, 2H), 1.10 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ
162.52, 153.35, 141.97, 140.73, 131.82, 130.54, 127.40, 124.46, 123.86,
123.82, 122.93, 120.16, 119.48, 53.06 (2C), 52.65 (2C), 47.56, 12.18.
HPLC purity 100%, RT 3.122 min. MS (ESI) 307.2 [M + H]+. HRMS
(ESI) calcd for C19H23N4
+ [M + H]+: 307.1917. Found: 307.1918.
4-(5H-Dibenzo[b,e][1,4]diazepin-11-yl)-1-ethylpiperazine N-
oxide (23). A solution of compound 22 (0.095 g, 0.31 mmol) in
CH2Cl2 (10 mL) was treated with mCPBA (0.069 g) at room
temperature. After 10 min, the reaction mixture was concentrated and
the residue was purified with 0−10% C (5% NH4OH in MeOH) in
CH2Cl2 to afford the desired product 23 (0.078 g) in 78% yield:
1H
NMR (400 MHz, MeOH-d4) δ 7.39−7.29 (m, 2H), 7.07−6.97 (m,
3H), 6.96−6.82 (m, 3H), 3.84 (br s, 2H), 3.79−3.66 (m, 2H), 3.56−
3.43 (m, 2H), 3.35 (q, J = 7.0 Hz, 2H), 3.18−3.07 (m, 2H), 1.37 (t, J =
7.1 Hz, 3H). 13C NMR (101 MHz, MeOH-d4) δ 163.66, 155.93,
144.50, 141.44, 133.64, 131.23, 127.98, 125.69, 125.05, 124.16, 124.13,
121.44, 120.80, 66.90 (2C), 63.79 (2C), 43.32, 7.70. HPLC purity
100%, RT 3.312 min. MS (ESI) 323.2 [M + H]+. HRMS (ESI) calcd
for C19H23N4O
+ [M + H]+: 323.1866. Found: 323.1863.
Biological Assays. hM3Dq and hM3 FLIPR assays were
performed according to the protocols reported previously.11,46,47
Protocols for 5-HT2A, 5-HT2C, α1A, and H1 radioligand binding assays
are available at the National Institute of Mental Health−Psychoactive
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